Savant HWP

Savant HWP, Inc., is a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues including Chagas disease and Leishmaniasis. The company's lead program is focused on the development of 18-MC, a novel compound that targets the dopamine "reward" pathway in the brain that drives pleasure-seeking behaviors associated with addiction, obesity and many forms of compulsive behavior.